Abstracts

Discovery and Development of New Antiepileptic Drugs Through NINDS Blueprint Neurotherapeutics Network (BPN)

Abstract number : 1.145
Submission category : 2. Translational Research / 2E. Other
Year : 2022
Submission ID : 2204646
Source : www.aesnet.org
Presentation date : 12/3/2022 12:00:00 PM
Published date : Nov 22, 2022, 05:25 AM

Authors :
Shamsi Raeissi, PhD – NINDS-NIH; Pascal Laeng, PhD – NINDS; Mohamed Hachicha, PhD – NINDS; Mary Pelleymounter – NINDS; Rebecca Roof – NINDS; Enrique Michelotti - National Institute of Mental Health; Carol Taylor-Burds – NINDS; Oreisa O’Neil-Mathurin – NINDS; Ranga Rangarajan – NINDS; Brian Klein – NINDS; Vicky Whittemore – NINDS; Charles Cywin, PhD – NINDS

Rationale: During the past decade, remarkable progress has been made on understanding the factors that contribute to different forms of epilepsy. Biotechnology advances in microRNA, small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) and induced Pluripotent Stem Cells (iPSC) research have also unveiled many pathways that are potential targets for new therapeutic approaches. Conversely, most of the potential neurotherapeutic drugs identified in basic research labs do not make it to clinical testing due to lack of relevant infrastructure, and resources.

Methods: To boost drug discovery and development efforts in the neuroscience field, the division of translational research (DTR) within NINDS, and in collaboration with other NIH-institutes, launched a series of translational programs to promote neuroscience drug discovery and development efforts to mitigate the current pipeline gaps. 

Results: In this presentation, we outline NINDS/DTR-BPN funding mechanism and resources available to academia and industry neuroscientists to accelerate their translation research into new therapies and support their ongoing preclinical development in the neuroscience field.

Conclusions: BPN knowhow has contributed to successful translation of an antiepileptic drug discovery project. 

Funding: Division of Translational Research, NINDS
Translational Research